Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
What's your choice of next line therapy for a metastatic papillary RCC who has progressed on cabozantinib?
Answer from: Medical Oncologist at Community Practice
Combination immunotherapy works well.
Sign in or Register to read more
15923
Related Questions
Do you hold or dose modify chemotherapy with BEP or EP for severe cytopenia or renal injury when treating testicular cancer in the curative setting?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
What are your top takeaways in GU Cancers from ESMO 2024?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
How do you manage dysgeusia from Enfortumab Vedotin?
Are you dose reducing/omitting IV dexamethasone as a pre-medication for anti-emesis in patients with MIBC when using durvalumab/gemcitabine/cisplatin?
What is your protocol for intermittent ADT for prostate cancer?
How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?